Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.64 |
| ▸ | FAAH | O00519 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818455 | 0.96 | CNR2 (0.69) | CNR2FAAHCYP1A2CYP19A1CYP2C9 | |
| SCHEMBL6813643 | 0.95 | CNR2 (0.68) | CNR2FAAHCYP1A2CYP19A1CYP2C9 | |
| SCHEMBL6815937 | 0.88 | ALDH1A1 (0.59) | CNR2FAAHHPGDHSD17B10ALDH1A1 | |
| SCHEMBL6819488 | 0.87 | CNR2 (0.53) | CNR2FAAHHPGDHSD17B10ALDH1A1 | |
| SCHEMBL6818570 | 0.86 | CNR2 (0.53) | CNR2FAAHHPGDHSD17B10ALDH1A1 | |
| SCHEMBL6819489 | 0.86 | CNR2 (0.54) | CNR2FAAHHPGDHSD17B10ALDH1A1 | |
| SCHEMBL10273358 | 0.86 | CNR2 (0.65) | CNR2FAAHHPGDHSD17B10ALDH1A1 | |
| SCHEMBL6814645 | 0.84 | ALDH1A1 (0.52) | CNR2FAAHHPGDHSD17B10ALDH1A1 | |
| SCHEMBL6818280 | 0.83 | CNR2 (0.66) | CNR2FAAHCYP1A2CYP19A1CYP2C9 | |
| SCHEMBL6814520 | 0.83 | PTPN1 (0.53) | CNR2FAAHHPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | CNR2 595/4885FAAH 159/4885CYP1A2 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.